Stock AIM AIM IMMUNOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Market Closed - Nyse
Other stock markets
 04:10:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.4065 USD -5.47% Intraday chart for AIM ImmunoTech Inc. -14.76% -7.59%
Apr. 10 AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer CI
Apr. 02 Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Evolution of the average Target Price on AIM ImmunoTech Inc.

Price target over the last 5 years

History of analyst recommendation changes

e46aec6930331b3fe4ac27d8c.WHUsB-74aypCUwa-lp7yl69U4ouVV1jT5WBrfOKcbFw.LyUVMLGcXFw0YHTr1au68cU7jPztbhyB0TcvTqX4Oz8wPR1qrY4tYXY7aQ~b8d37cd2b2c083d66ed096c1dde6eeb4

Analyst Recommendations on AIM ImmunoTech Inc.

Maxim Group Adjusts AIM ImmunoTech Price Target to $3 From $5, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.43 USD
Average target price
2.75 USD
Spread / Average Target
+539.53%
High Price Target
3.5 USD
Spread / Highest target
+713.95%
Low Price Target
2 USD
Spread / Lowest Target
+365.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AIM ImmunoTech Inc.

Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AIM Stock
  4. Consensus AIM ImmunoTech Inc.